Did the FDA make the right call on propoxyphene?
This article was originally published in Scrip
The decision by the US FDA at long last to pull propoxyphene-containing products from the US market (scripintelligence.com, 22 November 2010) has been greeted by the full gamut of responses, from those alleging it is part of a plot to force patients to use newer, more expensive medications to those who claim that the ruling is part of the Obama administration’s scheme to exert ever greater control over the individual.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.